WO2003068750A1 - Inhibiteur de jnk - Google Patents

Inhibiteur de jnk Download PDF

Info

Publication number: WO2003068750A1
Authority: WO; WIPO (PCT)
Prior art keywords: optionally substituted; compound; jnk inhibitor; optionally; thioesterified
Prior art date: 2002-02-13

Application number

PCT/JP2003/001429

Other languages

English (en)

French (fr)

Inventor

Fumio Itoh

Hiroyuki Kimura

Hideki Igata

Tomohiro Kawamoto

Mitsuru Sasaki

Shuji Kitamura

Original Assignee

Takeda Chemical Industries, Ltd.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-02-13

Filing date

2003-02-12

Publication date

2003-08-21

2003-02-12 Application filed by Takeda Chemical Industries, Ltd. filed Critical Takeda Chemical Industries, Ltd.

2003-02-12 Priority to EP03705075A priority Critical patent/EP1484320A1/en

2003-02-12 Priority to AU2003211931A priority patent/AU2003211931A1/en

2003-02-12 Priority to US10/504,132 priority patent/US7402595B2/en

2003-02-12 Priority to CA002476162A priority patent/CA2476162A1/en

2003-08-21 Publication of WO2003068750A1 publication Critical patent/WO2003068750A1/ja

Links

229940118135 JNK inhibitor Drugs 0.000 title abstract 2
239000012825 JNK inhibitor Substances 0.000 title abstract 2
150000001875 compounds Chemical class 0.000 abstract 3
125000002252 acyl group Chemical group 0.000 abstract 1
125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
125000000623 heterocyclic group Chemical group 0.000 abstract 1
125000001183 hydrocarbyl group Chemical group 0.000 abstract 1
229910052739 hydrogen Inorganic materials 0.000 abstract 1
239000001257 hydrogen Substances 0.000 abstract 1
125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
VDBNYAPERZTOOF-UHFFFAOYSA-N isoquinolin-1(2H)-one Chemical group C1=CC=C2C(=O)NC=CC2=C1 VDBNYAPERZTOOF-UHFFFAOYSA-N 0.000 abstract 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/24—Oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Epidemiology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Physical Education & Sports Medicine (AREA)
Hospice & Palliative Care (AREA)
Urology & Nephrology (AREA)
Dermatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Psychology (AREA)
Hematology (AREA)
Pulmonology (AREA)
Psychiatry (AREA)
Vascular Medicine (AREA)
Gastroenterology & Hepatology (AREA)
Diabetes (AREA)
Immunology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

PCT/JP2003/001429 2002-02-13 2003-02-12 Inhibiteur de jnk WO2003068750A1 (fr)

Priority Applications (4)

Application Number	Priority Date	Filing Date	Title
EP03705075A EP1484320A1 (en)	2002-02-13	2003-02-12	Jnk inhibitor
AU2003211931A AU2003211931A1 (en)	2002-02-13	2003-02-12	Jnk inhibitor
US10/504,132 US7402595B2 (en)	2002-02-13	2003-02-12	JNK inhibitor
CA002476162A CA2476162A1 (en)	2002-02-13	2003-02-12	Jnk inhibitor

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
JP2002035073		2002-02-13
JP2002-35073		2002-02-13
JP2002-251997		2002-08-29
JP2002251997		2002-08-29

Publications (1)

Publication Number	Publication Date
WO2003068750A1 true WO2003068750A1 (fr)	2003-08-21

Family

ID=27736487

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PCT/JP2003/001429 WO2003068750A1 (fr)	2002-02-13	2003-02-12	Inhibiteur de jnk

Country Status (5)

Country	Link
US (1)	US7402595B2 (ja)
EP (1)	EP1484320A1 (ja)
AU (1)	AU2003211931A1 (ja)
CA (1)	CA2476162A1 (ja)
WO (1)	WO2003068750A1 (ja)

Cited By (43)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2004054979A1 (ja) *	2002-12-18	2004-07-01	Takeda Pharmaceutical Company Limited	Ｊｎｋ阻害剤
WO2005014576A1 (ja) *	2003-08-12	2005-02-17	Takeda Pharmaceutical Company Limited	イソキノリノン誘導体、その製造法および用途
EP1604983A1 (en) *	2003-03-17	2005-12-14	Takeda Pharmaceutical Company Limited	Receptor antagonist
EP1676574A2 (en)	2004-12-30	2006-07-05	Johnson & Johnson Vision Care, Inc.	Methods for promoting survival of transplanted tissues and cells
JP2007506679A (ja) *	2003-09-23	2007-03-22	メルク　エンド　カムパニー　インコーポレーテッド	イソキノリノンカリウムチャネル阻害剤
JP2007506748A (ja) *	2003-09-23	2007-03-22	メルク　エンド　カムパニー　インコーポレーテッド	イソキノリノンカリウムチャネル阻害剤
JP2007506740A (ja) *	2003-09-23	2007-03-22	メルク　エンド　カムパニー　インコーポレーテッド	イソキノリノンカリウムチャネル阻害剤
JP2007516218A (ja) *	2003-09-23	2007-06-21	メルク　エンド　カムパニー　インコーポレーテッド	イソキノリノンカリウムチャネル阻害剤
JP2008513414A (ja) *	2004-09-17	2008-05-01	ジャンセンファーマシュウティカルエヌヴィ	新規ピリジノン誘導体およびｍＧｌｕＲ２ポジティブアロステリックモジュレーターとしてのその使用
US8252937B2 (en)	2007-09-14	2012-08-28	Janssen Pharmaceuticals, Inc.	1,3-disubstituted 4-(aryl-X-phenyl)-1H-pyridin-2-ones
US8299101B2 (en)	2007-03-07	2012-10-30	Janssen Pharmaceuticals, Inc.	1,4-disubstituted 3-cyano-pyridone derivatives and their use as positive mGluR2-receptor modulators
US8501812B2 (en)	2005-03-29	2013-08-06	University Of Massachusetts	Therapeutic methods for type I diabetes
US8691813B2 (en)	2008-11-28	2014-04-08	Janssen Pharmaceuticals, Inc.	Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors
US8691849B2 (en)	2008-09-02	2014-04-08	Janssen Pharmaceuticals, Inc.	3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors
US8841323B2 (en)	2006-03-15	2014-09-23	Janssen Pharmaceuticals, Inc.	1, 4-disubstituted 3-cyano-pyridone derivatives and their use as positive allosteric modulators of MGLUR2-receptors
US8906939B2 (en)	2007-03-07	2014-12-09	Janssen Pharmaceuticals, Inc.	3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
US8937060B2 (en)	2009-05-12	2015-01-20	Janssen Pharmaceuticals, Inc.	1,2,4-triazolo [4,3-A] pyridine derivatives and their use for the treatment of prevention of neurological and psychiatric disorders
US8940752B2 (en)	2009-06-29	2015-01-27	Incyte Corporation	Pyrimidinones as PI3K inhibitors
US8946205B2 (en)	2009-05-12	2015-02-03	Janssen Pharmaceuticals, Inc.	1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
US8993591B2 (en)	2010-11-08	2015-03-31	Janssen Pharmaceuticals, Inc.	1,2,4-triazolo[4,3-a] pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors
US9012448B2 (en)	2010-11-08	2015-04-21	Janssen Pharmaceuticals, Inc.	1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors
US9062055B2 (en)	2010-06-21	2015-06-23	Incyte Corporation	Fused pyrrole derivatives as PI3K inhibitors
US9085577B2 (en)	2009-05-12	2015-07-21	Janssen Pharmaceuticals, Inc.	7-aryl-1,2,4-triazolo[4,3-A]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
US9096600B2 (en)	2010-12-20	2015-08-04	Incyte Corporation	N-(1-(substituted-phenyl)ethyl)-9H-purin-6-amines as PI3K inhibitors
US9108984B2 (en)	2011-03-14	2015-08-18	Incyte Corporation	Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors
US9114138B2 (en)	2007-09-14	2015-08-25	Janssen Pharmaceuticals, Inc.	1′,3′-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2H,1′H-[1,4′] bipyridinyl-2′-ones
US9126948B2 (en)	2011-03-25	2015-09-08	Incyte Holdings Corporation	Pyrimidine-4,6-diamine derivatives as PI3K inhibitors
US9193721B2 (en)	2010-04-14	2015-11-24	Incyte Holdings Corporation	Fused derivatives as PI3Kδ inhibitors
US9199982B2 (en)	2011-09-02	2015-12-01	Incyte Holdings Corporation	Heterocyclylamines as PI3K inhibitors
US9221767B2 (en)	2013-01-18	2015-12-29	Bristol-Myers Squibb Company	Substituted phthalazinones as rock inhibitors
US9271967B2 (en)	2010-11-08	2016-03-01	Janssen Pharmaceuticals, Inc.	1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
US9309251B2 (en)	2012-04-02	2016-04-12	Incyte Holdings Corporation	Bicyclic azaheterocyclobenzylamines as PI3K inhibitors
US9403847B2 (en)	2009-12-18	2016-08-02	Incyte Holdings Corporation	Substituted heteroaryl fused derivatives as P13K inhibitors
US9708315B2 (en)	2013-09-06	2017-07-18	Janssen Pharmaceutica Nv	1,2,4-triazolo[4,3-a]pyridine compounds and their use as positive allosteric modulators of MGLUR2 receptors
US9732097B2 (en)	2015-05-11	2017-08-15	Incyte Corporation	Process for the synthesis of a phosphoinositide 3-kinase inhibitor
US9902702B2 (en)	2014-07-15	2018-02-27	Bristol-Myers Squibb Company	Spirocycloheptanes as inhibitors of rock
US9988401B2 (en)	2015-05-11	2018-06-05	Incyte Corporation	Crystalline forms of a PI3K inhibitor
US10077277B2 (en)	2014-06-11	2018-09-18	Incyte Corporation	Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors
US10106542B2 (en)	2013-06-04	2018-10-23	Janssen Pharmaceutica Nv	Substituted 6,7-dihydropyrazolo[1,5-a]pyrazines as negative allosteric modulators of mGluR2 receptors
US10336759B2 (en)	2015-02-27	2019-07-02	Incyte Corporation	Salts and processes of preparing a PI3K inhibitor
US10537573B2 (en)	2014-01-21	2020-01-21	Janssen Pharmaceutica Nv	Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
US11369606B2 (en)	2014-01-21	2022-06-28	Janssen Pharmaceutica Nv	Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
US12226418B2 (en)	2018-06-01	2025-02-18	Incyte Corporation	Dosing regimen for the treatment of PI3K related disorders

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2879458B1 (fr) *	2004-12-21	2007-07-20	Centre Nat Rech Scient Cnrse	Sulfamides et sulfinimides fluores
US9623021B2 (en)	2007-01-22	2017-04-18	Gtx, Inc.	Nuclear receptor binding agents
WO2008091555A2 (en)	2007-01-22	2008-07-31	Gtx, Inc.	Nuclear receptor binding agents
US9604931B2 (en)	2007-01-22	2017-03-28	Gtx, Inc.	Nuclear receptor binding agents
CL2008000973A1 (es) *	2007-04-05	2009-01-02	Astrazeneca Ab	Compuestos derivados de 1-oxo-isoquinolina; procedimiento de preparación; composición farmacéutica; y su uso en el tratamiento de enfermedades pulmonares obstructvas crónicas (epoc) y asma.
WO2009015917A2 (en) *	2007-05-14	2009-02-05	F. Hoffmann-La Roche Ag	Dihydroquinone and dihydronaphthridine inhibitors of jnk
FR2925899B1 (fr) *	2007-12-27	2012-12-21	Sidem Pharma Sa	Procede de preparation enantioselective de sulfoxydes.
WO2009111264A2 (en) *	2008-02-29	2009-09-11	Alseres Pharmaceuticals, Inc.	Systemic purine administration:modulating axonal outgrowth of central nervous system neurons
AR073711A1 (es)	2008-10-01	2010-11-24	Astrazeneca Ab	Derivados de isoquinolina
JP2010254672A (ja) *	2009-03-30	2010-11-11	Santen Pharmaceut Co Ltd	ＪＮＫ（ｃ−Ｊｕｎアミノ末端キナーゼ）阻害ペプチドを有効成分として含有する網膜疾患の予防または治療剤
US9974850B2 (en) *	2013-01-25	2018-05-22	Board Of Regents, The University Of Texas System	Immunogenic compositions and uses thereof
EA035727B1 (ru) *	2013-10-18	2020-07-31	Селджен Квонтисел Рисёрч, Инк.	Ингибиторы бромодомена
US9765097B2 (en) *	2014-06-23	2017-09-19	Nissan Chemical Industries, Ltd.	Method for producing silane compound having sulfonyl bond
ES2949982T3 (es) *	2014-06-26	2023-10-04	Xigen Inflammation Ltd	Inhibidores peptídicos permeables en células de la ruta de transducción de señales de JNK para el tratamiento de la cistitis

Citations (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH10298164A (ja) *	1997-02-27	1998-11-10	Tanabe Seiyaku Co Ltd	イソキノリノン誘導体、その製法及びその合成中間体
WO2000000491A1 (en) *	1998-06-29	2000-01-06	The Regents Of The University Of California	Bifunctional antagonists of cytokine-sensitive protein kinase activation cascades and methods for use as anti-inflammatory agents
JP2000072751A (ja) *	1998-08-26	2000-03-07	Tanabe Seiyaku Co Ltd	イソキノリノン誘導体
JP2000072675A (ja) *	1998-08-26	2000-03-07	Tanabe Seiyaku Co Ltd	医薬組成物
WO2002010137A2 (en) *	2000-07-31	2002-02-07	Signal Pharmaceuticals, Inc.	Indazole derivatives as jnk inhibitors
WO2002062764A1 (en) *	2001-02-02	2002-08-15	Takeda Chemical Industries, Ltd.	Fused heterocyclic compounds
WO2002081475A1 (en) *	2001-04-06	2002-10-17	Eisai Co., Limited	Jun kinase inhibitors
US6486155B1 (en) *	1998-11-24	2002-11-26	Cell Pathways Inc	Method of inhibiting neoplastic cells with isoquinoline derivatives

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE124408T1 (de) *	1990-10-16	1995-07-15	Takeda Chemical Industries Ltd	Heterozyklische aminderivate, deren herstellung und deren verwendung.
TW241258B (ja) *	1992-04-15	1995-02-21	Takeda Pharm Industry Co Ltd
ATE161530T1 (de) *	1992-09-04	1998-01-15	Takeda Chemical Industries Ltd	Kondensierte heterozyklische verbindungen, deren herstellung und verwendung
EP0634402A1 (en) *	1993-07-14	1995-01-18	Takeda Chemical Industries, Ltd.	Isochinolinone derivatives, their production and use
TW263498B (ja) *	1993-11-10	1995-11-21	Takeda Pharm Industry Co Ltd
WO1998038168A1 (en)	1997-02-27	1998-09-03	Tanabe Seiyaku Co., Ltd.	Isoquinolinone derivatives, process for preparing the same, and their use as phosphodiesterase inhibitors

2003
- 2003-02-12 CA CA002476162A patent/CA2476162A1/en not_active Abandoned
- 2003-02-12 EP EP03705075A patent/EP1484320A1/en not_active Withdrawn
- 2003-02-12 US US10/504,132 patent/US7402595B2/en not_active Expired - Fee Related
- 2003-02-12 AU AU2003211931A patent/AU2003211931A1/en not_active Abandoned
- 2003-02-12 WO PCT/JP2003/001429 patent/WO2003068750A1/ja active Application Filing

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH10298164A (ja) *	1997-02-27	1998-11-10	Tanabe Seiyaku Co Ltd	イソキノリノン誘導体、その製法及びその合成中間体
WO2000000491A1 (en) *	1998-06-29	2000-01-06	The Regents Of The University Of California	Bifunctional antagonists of cytokine-sensitive protein kinase activation cascades and methods for use as anti-inflammatory agents
JP2000072751A (ja) *	1998-08-26	2000-03-07	Tanabe Seiyaku Co Ltd	イソキノリノン誘導体
JP2000072675A (ja) *	1998-08-26	2000-03-07	Tanabe Seiyaku Co Ltd	医薬組成物
US6486155B1 (en) *	1998-11-24	2002-11-26	Cell Pathways Inc	Method of inhibiting neoplastic cells with isoquinoline derivatives
WO2002010137A2 (en) *	2000-07-31	2002-02-07	Signal Pharmaceuticals, Inc.	Indazole derivatives as jnk inhibitors
WO2002062764A1 (en) *	2001-02-02	2002-08-15	Takeda Chemical Industries, Ltd.	Fused heterocyclic compounds
WO2002081475A1 (en) *	2001-04-06	2002-10-17	Eisai Co., Limited	Jun kinase inhibitors

Cited By (84)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2004054979A1 (ja) *	2002-12-18	2004-07-01	Takeda Pharmaceutical Company Limited	Ｊｎｋ阻害剤
EP1604983A4 (en) *	2003-03-17	2008-06-25	Takeda Pharmaceutical	Receptor Antagonists
EP1604983A1 (en) *	2003-03-17	2005-12-14	Takeda Pharmaceutical Company Limited	Receptor antagonist
WO2005014576A1 (ja) *	2003-08-12	2005-02-17	Takeda Pharmaceutical Company Limited	イソキノリノン誘導体、その製造法および用途
JP4717815B2 (ja) *	2003-09-23	2011-07-06	メルク・シャープ・エンド・ドーム・コーポレイション	イソキノリノンカリウムチャネル阻害剤
JP2007506748A (ja) *	2003-09-23	2007-03-22	メルク　エンド　カムパニー　インコーポレーテッド	イソキノリノンカリウムチャネル阻害剤
JP2007506740A (ja) *	2003-09-23	2007-03-22	メルク　エンド　カムパニー　インコーポレーテッド	イソキノリノンカリウムチャネル阻害剤
JP2007516218A (ja) *	2003-09-23	2007-06-21	メルク　エンド　カムパニー　インコーポレーテッド	イソキノリノンカリウムチャネル阻害剤
JP2007506679A (ja) *	2003-09-23	2007-03-22	メルク　エンド　カムパニー　インコーポレーテッド	イソキノリノンカリウムチャネル阻害剤
JP4719152B2 (ja) *	2003-09-23	2011-07-06	メルク・シャープ・エンド・ドーム・コーポレイション	イソキノリノンカリウムチャネル阻害剤
JP4719151B2 (ja) *	2003-09-23	2011-07-06	メルク・シャープ・エンド・ドーム・コーポレイション	イソキノリノンカリウムチャネル阻害剤
JP4718467B2 (ja) *	2003-09-23	2011-07-06	メルク・シャープ・エンド・ドーム・コーポレイション	イソキノリノンカリウムチャネル阻害剤
JP2008513414A (ja) *	2004-09-17	2008-05-01	ジャンセンファーマシュウティカルエヌヴィ	新規ピリジノン誘導体およびｍＧｌｕＲ２ポジティブアロステリックモジュレーターとしてのその使用
JP2013047254A (ja) *	2004-09-17	2013-03-07	Ortho-Mcneil-Janssen Pharmaceuticals Inc	新規ピリジノン誘導体およびｍＧｌｕＲ２ポジティブアロステリックモジュレーターとしてのその使用
US8399493B2 (en)	2004-09-17	2013-03-19	Janssen Pharmaceuticals, Inc.	Pyridinone derivatives and their use as positive allosteric modulators of mGluR2-receptors
EP1676574A2 (en)	2004-12-30	2006-07-05	Johnson & Johnson Vision Care, Inc.	Methods for promoting survival of transplanted tissues and cells
US8501812B2 (en)	2005-03-29	2013-08-06	University Of Massachusetts	Therapeutic methods for type I diabetes
US8841323B2 (en)	2006-03-15	2014-09-23	Janssen Pharmaceuticals, Inc.	1, 4-disubstituted 3-cyano-pyridone derivatives and their use as positive allosteric modulators of MGLUR2-receptors
US9067891B2 (en)	2007-03-07	2015-06-30	Janssen Pharmaceuticals, Inc.	1,4-disubstituted 3-cyano-pyridone derivatives and their use as positive allosteric modulators of mGluR2-receptors
US8299101B2 (en)	2007-03-07	2012-10-30	Janssen Pharmaceuticals, Inc.	1,4-disubstituted 3-cyano-pyridone derivatives and their use as positive mGluR2-receptor modulators
US8906939B2 (en)	2007-03-07	2014-12-09	Janssen Pharmaceuticals, Inc.	3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
US11071729B2 (en)	2007-09-14	2021-07-27	Addex Pharmaceuticals S.A.	1′,3′-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2H,1′H-[1,4′]bipyridinyl-2′-ones
US9114138B2 (en)	2007-09-14	2015-08-25	Janssen Pharmaceuticals, Inc.	1′,3′-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2H,1′H-[1,4′] bipyridinyl-2′-ones
US8252937B2 (en)	2007-09-14	2012-08-28	Janssen Pharmaceuticals, Inc.	1,3-disubstituted 4-(aryl-X-phenyl)-1H-pyridin-2-ones
US9132122B2 (en)	2007-09-14	2015-09-15	Janssen Pharmaceuticals, Inc.	1′,3′-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2H,1′H-[1,4′]bipyridinyl-2′-ones
US8691849B2 (en)	2008-09-02	2014-04-08	Janssen Pharmaceuticals, Inc.	3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors
US8691813B2 (en)	2008-11-28	2014-04-08	Janssen Pharmaceuticals, Inc.	Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors
US8937060B2 (en)	2009-05-12	2015-01-20	Janssen Pharmaceuticals, Inc.	1,2,4-triazolo [4,3-A] pyridine derivatives and their use for the treatment of prevention of neurological and psychiatric disorders
US8946205B2 (en)	2009-05-12	2015-02-03	Janssen Pharmaceuticals, Inc.	1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
US9737533B2 (en)	2009-05-12	2017-08-22	Janssen Pharmaceuticals. Inc.	1,2,4-triazolo [4,3-A] pyridine derivatives and their use for the treatment of prevention of neurological and psychiatric disorders
US9226930B2 (en)	2009-05-12	2016-01-05	Janssen Pharmaceuticals, Inc.	1,2,4-triazolo [4,3-a] pyridine derivatives and their use for the treatment of prevention of neurological and psychiatric disorders
US9085577B2 (en)	2009-05-12	2015-07-21	Janssen Pharmaceuticals, Inc.	7-aryl-1,2,4-triazolo[4,3-A]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
US10071095B2 (en)	2009-05-12	2018-09-11	Janssen Pharmaceuticals, Inc.	1,2,4-triazolo [4,3-A] pyridine derivatives and their use for the treatment of neurological and psychiatric disorders
US11401280B2 (en)	2009-06-29	2022-08-02	Incyte Holdings Corporation	Pyrimidinones as PI3K inhibitors
US9975907B2 (en)	2009-06-29	2018-05-22	Incyte Holdings Corporation	Pyrimidinones as PI3K inhibitors
US10428087B2 (en)	2009-06-29	2019-10-01	Incyte Corporation	Pyrimidinones as PI3K inhibitors
US10829502B2 (en)	2009-06-29	2020-11-10	Incyte Corporation	Pyrimidinones as PI3K inhibitors
US9434746B2 (en)	2009-06-29	2016-09-06	Incyte Corporation	Pyrimidinones as PI3K inhibitors
US8940752B2 (en)	2009-06-29	2015-01-27	Incyte Corporation	Pyrimidinones as PI3K inhibitors
US9403847B2 (en)	2009-12-18	2016-08-02	Incyte Holdings Corporation	Substituted heteroaryl fused derivatives as P13K inhibitors
US9193721B2 (en)	2010-04-14	2015-11-24	Incyte Holdings Corporation	Fused derivatives as PI3Kδ inhibitors
US9062055B2 (en)	2010-06-21	2015-06-23	Incyte Corporation	Fused pyrrole derivatives as PI3K inhibitors
US9012448B2 (en)	2010-11-08	2015-04-21	Janssen Pharmaceuticals, Inc.	1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors
US8993591B2 (en)	2010-11-08	2015-03-31	Janssen Pharmaceuticals, Inc.	1,2,4-triazolo[4,3-a] pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors
US9271967B2 (en)	2010-11-08	2016-03-01	Janssen Pharmaceuticals, Inc.	1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
US9815839B2 (en)	2010-12-20	2017-11-14	Incyte Corporation	N-(1-(substituted-phenyl)ethyl)-9H-purin-6-amines as PI3K inhibitors
US9096600B2 (en)	2010-12-20	2015-08-04	Incyte Corporation	N-(1-(substituted-phenyl)ethyl)-9H-purin-6-amines as PI3K inhibitors
US9527848B2 (en)	2010-12-20	2016-12-27	Incyte Holdings Corporation	N-(1-(substituted-phenyl)ethyl)-9H-purin-6-amines as PI3K inhibitors
US9108984B2 (en)	2011-03-14	2015-08-18	Incyte Corporation	Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors
US9126948B2 (en)	2011-03-25	2015-09-08	Incyte Holdings Corporation	Pyrimidine-4,6-diamine derivatives as PI3K inhibitors
US10092570B2 (en)	2011-09-02	2018-10-09	Incyte Holdings Corporation	Heterocyclylamines as PI3K inhibitors
US10646492B2 (en)	2011-09-02	2020-05-12	Incyte Corporation	Heterocyclylamines as PI3K inhibitors
US11433071B2 (en)	2011-09-02	2022-09-06	Incyte Corporation	Heterocyclylamines as PI3K inhibitors
US9730939B2 (en)	2011-09-02	2017-08-15	Incyte Holdings Corporation	Heterocyclylamines as PI3K inhibitors
US12201636B2 (en)	2011-09-02	2025-01-21	Incyte Corporation	Heterocyclylamines as PI3K inhibitors
US9199982B2 (en)	2011-09-02	2015-12-01	Incyte Holdings Corporation	Heterocyclylamines as PI3K inhibitors
US9707233B2 (en)	2011-09-02	2017-07-18	Incyte Holdings Corporation	Heterocyclylamines as PI3K inhibitors
US10376513B2 (en)	2011-09-02	2019-08-13	Incyte Holdings Corporation	Heterocyclylamines as PI3K inhibitors
US11819505B2 (en)	2011-09-02	2023-11-21	Incyte Corporation	Heterocyclylamines as PI3K inhibitors
US10259818B2 (en)	2012-04-02	2019-04-16	Incyte Corporation	Bicyclic azaheterocyclobenzylamines as PI3K inhibitors
US9309251B2 (en)	2012-04-02	2016-04-12	Incyte Holdings Corporation	Bicyclic azaheterocyclobenzylamines as PI3K inhibitors
US9944646B2 (en)	2012-04-02	2018-04-17	Incyte Holdings Corporation	Bicyclic azaheterocyclobenzylamines as PI3K inhibitors
US9926282B2 (en)	2013-01-18	2018-03-27	Bristol-Myers Squibb Company	Phthalazinones and isoquinolinones as rock inhibitors
US10385026B2 (en)	2013-01-18	2019-08-20	Bristol-Myers Squibb Company	Phthalazinones and isoquinolinones as rock inhibitors
US9221767B2 (en)	2013-01-18	2015-12-29	Bristol-Myers Squibb Company	Substituted phthalazinones as rock inhibitors
US10584129B2 (en)	2013-06-04	2020-03-10	Janssen Pharmaceuticals Nv	Substituted 6,7-dihydropyrazolo[1,5-a]pyrazines as negative allosteric modulators of mGluR2 receptors
US10106542B2 (en)	2013-06-04	2018-10-23	Janssen Pharmaceutica Nv	Substituted 6,7-dihydropyrazolo[1,5-a]pyrazines as negative allosteric modulators of mGluR2 receptors
US9708315B2 (en)	2013-09-06	2017-07-18	Janssen Pharmaceutica Nv	1,2,4-triazolo[4,3-a]pyridine compounds and their use as positive allosteric modulators of MGLUR2 receptors
US10537573B2 (en)	2014-01-21	2020-01-21	Janssen Pharmaceutica Nv	Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
US12048696B2 (en)	2014-01-21	2024-07-30	Janssen Pharmaceutica Nv	Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
US11103506B2 (en)	2014-01-21	2021-08-31	Janssen Pharmaceutica Nv	Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
US11369606B2 (en)	2014-01-21	2022-06-28	Janssen Pharmaceutica Nv	Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
US10479803B2 (en)	2014-06-11	2019-11-19	Incyte Corporation	Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors
US10077277B2 (en)	2014-06-11	2018-09-18	Incyte Corporation	Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors
US11999751B2 (en)	2014-06-11	2024-06-04	Incyte Corporation	Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors
US11130767B2 (en)	2014-06-11	2021-09-28	Incyte Corporation	Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors
US9902702B2 (en)	2014-07-15	2018-02-27	Bristol-Myers Squibb Company	Spirocycloheptanes as inhibitors of rock
US11084822B2 (en)	2015-02-27	2021-08-10	Incyte Corporation	Salts and processes of preparing a PI3K inhibitor
US10336759B2 (en)	2015-02-27	2019-07-02	Incyte Corporation	Salts and processes of preparing a PI3K inhibitor
US12024522B2 (en)	2015-02-27	2024-07-02	Incyte Corporation	Salts and processes of preparing a PI3K inhibitor
US10125150B2 (en)	2015-05-11	2018-11-13	Incyte Corporation	Crystalline forms of a PI3K inhibitor
US9988401B2 (en)	2015-05-11	2018-06-05	Incyte Corporation	Crystalline forms of a PI3K inhibitor
US9732097B2 (en)	2015-05-11	2017-08-15	Incyte Corporation	Process for the synthesis of a phosphoinositide 3-kinase inhibitor
US12226418B2 (en)	2018-06-01	2025-02-18	Incyte Corporation	Dosing regimen for the treatment of PI3K related disorders

Also Published As

Publication number	Publication date
US20050148624A1 (en)	2005-07-07
CA2476162A1 (en)	2003-08-21
EP1484320A1 (en)	2004-12-08
US7402595B2 (en)	2008-07-22
AU2003211931A1 (en)	2003-09-04

Legal Events

Date	Code	Title	Description
2003-08-21	AK	Designated states	Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW
2003-08-21	AL	Designated countries for regional patents	Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
2003-09-25	DFPE	Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
2003-10-15	121	Ep: the epo has been informed by wipo that ep was designated in this application
2004-08-11	WWE	Wipo information: entry into national phase	Ref document number: 10504132 Country of ref document: US
2004-08-12	WWE	Wipo information: entry into national phase	Ref document number: 2476162 Country of ref document: CA
2004-09-09	WWE	Wipo information: entry into national phase	Ref document number: 2003705075 Country of ref document: EP
2004-12-08	WWP	Wipo information: published in national office	Ref document number: 2003705075 Country of ref document: EP
2005-05-17	NENP	Non-entry into the national phase	Ref country code: JP

Publication	Publication Date	Title
WO2003068750A1 (fr)	2003-08-21	Inhibiteur de jnk
RS51444B (sr)	2011-04-30	JEDINJENJA KOJA SADRŽE LAKTAM I NJIHOVI DERIVATI KAO INHIBITORI FAKTORA Xa
WO2007014054A3 (en)	2007-11-15	Benzenesulfonamide inhibitor of ccr2 chemokine receptor
NZ541974A (en)	2009-03-31	Nucleotide phosphoramidates as anticancer agents
WO2005061458A3 (en)	2005-10-13	Phosphodiesterase 4 inhibitors, including n-substituted diarylamine analogs
WO2003048081A3 (en)	2003-09-12	Glycinamides as factor xa inhibitors
MXPA06001273A (es)	2006-04-11	Compuestos novedosos.
EP1889842A4 (en)	2009-07-29	HETEROCYCLIC CONNECTION
WO2001030781A3 (en)	2001-11-22	INHIBITORS OF αLβ2 MEDIATED CELL ADHESION
AU2420897A (en)	1997-10-22	Meta-substituted phenylene sulphonamide derivatives
CA2534024A1 (en)	2005-02-10	Novel compounds having inhibitory activity against sodium-dependant transporter
EP1674452A4 (en)	2007-10-10	NOVEL 4-PHENYLAMINO-BENZALDOXIME DERIVATIVE AND ITS USE AS MEK INHIBITOR
CA2441474A1 (en)	2002-08-29	Composition and method for inhibition of formation of gas hydrates
WO2004014860A3 (en)	2004-05-21	Fused heterocyclic compounds as peptidase inhibitors
WO1999000373A8 (fr)	2000-07-20	Derives de benzimidazole
EP0867180A4 (en)	1999-09-15	VASCULAR PERMEATION INHIBITOR
WO2004031145A3 (en)	2004-07-01	Lactam-containing diaminoalkyl, beta-aminoacids, alpha-aminoacids and derivatives thereof as factor xa inhibitors
EP1295867A4 (en)	2005-03-30	BIPHENYL COMPOUND
WO2003014110A1 (fr)	2003-02-20	Derive de benzazepine, son procede de preparation et d'utilisation
AU7824900A (en)	2001-04-23	Compounds and methods for inhibiting mrp1
WO2005105096A3 (en)	2006-07-06	Fused heterocyclic compounds
MY140749A (en)	2010-01-15	Novel piperidine compound
CA2307581A1 (en)	1999-05-14	Heterocyclic compounds having nos inhibiting action
WO2003035650A1 (fr)	2003-05-01	Inhibiteur d'entree
EP1479681A4 (en)	2006-05-10	IMIDAZO (1,2-a) pyridine